Full-Time

Director of GI/Inflammation and Neuroscience-Biologics In Vitro Pharmacology

Posted on 3/13/2025

Takeda

Takeda

10,001+ employees

Develops and commercializes biopharmaceuticals and vaccines

Compensation Overview

$169.4k - $266.2kAnnually

+ Short-term Incentives + Long-term Incentives

Senior, Expert

Boston, MA, USA

Category
Lab & Research
Medical Research
Requirements
  • PhD degree in immunology or a related scientific discipline with 10+ years’ experience.
  • Minimum of 10 years of experience in GI/Inflammation and Neuroscience research, with at least 7 years industry experience in pharma, biotech with a track record of leading GI/inflammation and Neuroscience discovery projects, specifically in Autoimmune and inflammatory diseases.
  • Minimum of 7 years of management experience.
  • Expertise in biologics drug discovery and development processes, including hit identification, lead optimization, candidate selection, and preclinical development.
  • Proven track record of leading successful in vitro pharmacology efforts in the field of GI/Inflammation and Neuroscience, including assay development and validation, functional screening, and mechanism of action studies.
  • Strong technical proficiency in a wide range of in vitro pharmacology techniques and assay formats, including complex cell-based phenotypic assays, immune cell-based assays, co-culture systems, inflammation-based assays, neuronal models and GI organoid systems, flow cytometry, and high content imaging.
  • Excellent leadership, communication, and interpersonal skills, with the ability to lead a team and projects and collaborate effectively across disciplines, demonstrate enterprise leadership with an ability to influence without authority.
  • Knowledge of regulatory requirements and guidelines for drug discovery and development.
Responsibilities
  • Provide strategic direction to the GI/Inflammation and Neuroscience discovery project teams, ensuring alignment with company goals and objectives.
  • Oversee the strategy for functional evaluation and candidate selection of novel GI/ Inflammation and Neuroscience therapeutics.
  • Lead a team responsible for the design, development and execution of state-of-the-art in vitro pharmacology assays to evaluate the biological activity, potency, efficacy, and mechanism of action of our novel therapeutics, utilizing cutting-edge technologies (e.g., complex cell-based assays, co-culture systems, and 3D organoid models) to measure cellular responses in inflammatory pathways, and neuronal cell signaling.
  • Develop and implement innovative technologies to elevate our in vitro pharmacology capabilities and throughput to enhance translation and increase quality and efficiency. Stay abreast of the latest scientific advancements and industry trends.
  • Lead the GI/Inflammation and Neuroscience biologics discovery programs with cross-functional discovery teams, driving the programs from lead ID to preclinical development.
  • Build strong internal and external collaborations, foster alignment with our key stakeholders. Collaborate closely with interdisciplinary research teams in a matrix format, to advance discovery programs.
  • Mentor and develop team members, fostering a culture of innovation, collaboration, and scientific excellence.

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines. The company invests heavily in research and development to create new molecular entities (NMEs) and commercialize them, with a goal of launching up to 15 new products by FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to provide life-changing therapies while ensuring that patient needs are prioritized and environmental risks are managed.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's collaboration with BridGene could enhance its immunology and neurology offerings.
  • The SEA AtM Summit highlights Takeda's commitment to expanding access to medicines in Asia.
  • Positive Phase III trial results for a cancer drug strengthen Takeda's oncology portfolio.

What critics are saying

  • Antitrust litigation in the US could impact Takeda's market position and reputation.
  • The $770 million deal with BridGene poses financial risks if outcomes aren't met.
  • Geopolitical risks could disrupt Takeda's global operations and supply chain.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and innovations.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.

Nyasa Times
Feb 6th, 2025
Forgotten Children: Mzimba's Tukuyu CBCC Struggles to Provide Basic Education

VillageReach, in partnership with Takeda Pharmaceutical Company Limited, has launched a new initiative aimed at strengthening health systems and improving...